z-logo
open-access-imgOpen Access
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection
Author(s) -
Jordan J. Feld,
Ira M. Jacobson,
Christophe Hézode,
Tarik Asselah,
Peter Ruane,
Norbert H. Gruener,
Armand Abergel,
Alessandra Mangia,
ChingLung Lai,
Henry LikYuen Chan,
Francesco Mazzotta,
Christophe Moreno,
Eric M. Yoshida,
Stephen D. Shafran,
William Towner,
Tram T. Tran,
John McNally,
Anu Osinusi,
Evguenia S. Svarovskaia,
Yanni Zhu,
Diana M. Brainard,
John G. McHutchison,
Kosh Agarwal,
Stefan Zeuzem
Publication year - 2015
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1512610
Subject(s) - medicine , gastroenterology , sofosbuvir , placebo , hepatitis c virus , cirrhosis , genotype , regimen , hepatitis c , immunology , ribavirin , virus , pathology , biology , biochemistry , alternative medicine , gene
A simple treatment regimen that is effective in a broad range of patients who are chronically infected with the hepatitis C virus (HCV) remains an unmet medical need.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom